Cell Signaling Technology, Inc. (CST) of Danvers, MA, announced today that it has introduced a highly specific HER3 rabbit monoclonal antibody (mAb), an important addition for researchers studying HER2-mediated breast, lung and ovarian tumors. Although HER2 has been intensively studied for over 20 years, only recently has it come to light that HER3 may be required for HER2 transformation of normal cells in at least a subset of cancers. Preclinical research has also recently shown that HER3 activity may be a mechanism by which tumor cells escape inhibition.
CST's HER3 antibody is a rabbit monoclonal and therefore avoids well known background issues when using mouse antibodies for IHC in mouse xenograft models, which predominate in cancer research. Additionally, extensive testing has confirmed that there is no cross-reactivity with other family members, including EGFR, HER2/ErbB2, and HER4/ErbB4, enabling greater confidence in research results. The primary application for HER3 antibody research is IHC, and CST's HER3/ErbB3 XP® Rabbit mAb has been validated for IHC as well as Western Blot, Immunofluorescence (IF), and Flow Cytometry.
CST's Cancer Research Group has been focused on unraveling the signaling networks that underlie various cancers. Using innovative proteomic technologies, the study and analysis of the cancer proteome has identified the EML4-ALK fusion, which has been reported in a subset of patients with breast, colon and non-small cell lung cancer (NSCLC). Patents have been issued (8,486,645, 8,481,279, 8,377,642, 8,288,102, 8,232,060, 8,168,383, and 7,700,339) for EML4-ALK in NSCLC that span from research through diagnosis and therapy.
Tyrosine kinases play greater role in mitochondria than previously recognized